KRYS 주가 차트
KRYS 수입
Krystal Biotech Inc
$306.29
-3.16%
$-10
종가: May 15, 16:00:00 GMT-4
$319
4.14%
$12.7
애프터마켓: May 15, 20:00:00 GMT-4
뒤로
Krystal Biotech Inc (KRYS) 수입
최신 수익 결과: Q1 '26
보고됨: 2026-05-04
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
KRYS의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Krystal Biotech Inc KRYS의 지난 분기 매출 실적은 어땠나요?
Krystal Biotech Inc의 매출 추정치는 얼마인가요?
Krystal Biotech Inc의 수익 품질 점수는 얼마인가요?
Krystal Biotech Inc는 언제 수익을 보고하나요?
Krystal Biotech Inc의 예상 수익은 얼마인가요?
Krystal Biotech Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$316.3
시가
$312.29
일일 범위
$306.01 - $319
52주 범위
$122.8 - $319
거래량
316.3K
평균 거래량
300.2K
배당수익률
--
EPS(TTM)
7.48
시가총액
$9.3B
KRYS란 무엇인가요?
Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 295 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
